What’s Causing the Decline of Co-Diagnostics Stock on Tuesday?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 28 2025
0mins
Source: Benzinga
Stock Plunge: Co-Diagnostics, Inc. shares fell over 50% following the announcement of a $7 million direct offering and a new joint venture in Saudi Arabia, indicating investor concern over potential dilution.
Direct Offering Details: The company plans to sell 12.7 million shares at 55 cents each, with gross proceeds expected to be around $7 million, aimed at working capital and corporate purposes.
Joint Venture Agreement: Co-Diagnostics has partnered with Arabian Eagle to create CoMira Diagnostics, a Saudi joint venture focused on manufacturing and distributing Co-Dx technologies, aligning with Saudi Vision 2030.
Equity Offering Program: The company also disclosed an at-the-market equity offering program of up to $10 million, with Maxim Group LLC acting as the sales agent for the common stock sales.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CODX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CODX
Wall Street analysts forecast CODX stock price to fall
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 3.080
Low
1.50
Averages
1.50
High
1.50
Current: 3.080
Low
1.50
Averages
1.50
High
1.50
About CODX
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Co-Diagnostics Completes Clinical Performance Studies for PCR Test
- Clinical Study Completion: Co-Diagnostics has completed clinical and analytical performance studies for the Co-Dx™ PCR Flu A/B and RSV upper respiratory multiplex test across 9 clinical sites, enrolling over 1,400 patients, marking a significant milestone towards the FDA submission for 510(k) and CLIA Waiver.
- Analytical Validation Data: The studies included 27 individual analytical studies and over 10,000 PCR test cup runs, providing robust evidence to support the upcoming FDA submission targeted for Q3 2026, showcasing the company's potential in the decentralized testing market.
- Reproducibility Study: An external multicenter reproducibility study demonstrated consistent performance across different operators, sites, and instruments, meeting CLIA Waiver requirements and enhancing the product's competitive edge in the market.
- Strategic Vision: CEO Dwight Egan emphasized that the platform aims to deliver accurate near-patient PCR diagnostics, and the company's ongoing efforts and forthcoming submission will lay the groundwork for future commercialization, promoting the adoption of decentralized healthcare.
See More
Co-Diagnostics Expands Mosquito Abatement Customer Base
- Customer Base Growth: Co-Diagnostics has expanded its mosquito abatement district customer base to 21 states, with four new full laboratory installations added in June, reflecting the strength of its technology and the urgent need for vector-borne disease surveillance.
- Technological Advantage: The company's Vector Smart® product line includes multiplex PCR tests for various diseases such as West Nile virus and Zika, designed to enhance situational awareness in communities and improve abatement efficiency.
- Market Demand: According to the World Health Organization, vector-borne diseases cause over 700,000 deaths annually, and Co-Diagnostics' technology enables decentralized PCR testing within communities, facilitating better coordination among public health agencies.
- Commitment to Innovation: The company is committed to remaining at the forefront of decentralized PCR technology to support global vector control and infectious disease testing, ensuring timely collection and sharing of surveillance data to protect community health.
See More
Co-Diagnostics Advances Technology Transfer with CoMira Partnership
- Technology Transfer Initiative: Co-Diagnostics' delegation from CoMira Diagnostics visited the Salt Lake City headquarters, marking a new phase in the planned technology transfer that is expected to enhance diagnostic test production capabilities in Saudi Arabia and 18 other Middle Eastern and North African countries.
- Automated Production Line Unveiling: During the visit, Co-Diagnostics unveiled its future automated PCR test kit manufacturing line, a critical facility that will support rapid scaling of diagnostic test production to meet local healthcare needs and improve operational efficiency.
- Significance of International Collaboration: CEO Dwight Egan emphasized that the partnership with CoMira reflects the belief that closing the diagnostics gap requires a blend of cutting-edge technology and local expertise, aiming to enhance diagnostic accessibility across the region.
- AI-Integrated Platform: The Co-Dx PCR platform integrates artificial intelligence and cloud-connected outbreak surveillance capabilities, which are expected to be part of the CoMira partnership, reflecting the company's strategic intent to deploy automated, AI-driven diagnostic infrastructure in key international markets.
See More
Co-Diagnostics Advances Technology Transfer with CoMira Partnership
- Technology Transfer Initiative: Co-Diagnostics is set to transfer its molecular diagnostics platform and manufacturing capabilities to CoMira Diagnostics in Saudi Arabia, which is expected to significantly enhance diagnostic test production capacity in the region to meet healthcare needs.
- Automated Production Line Unveiling: The unveiling of the future automated PCR test kit manufacturing line at the Salt Lake City headquarters will support rapid scaling of diagnostic test production, anticipated to provide efficient testing solutions for Saudi Arabia and 18 other Middle Eastern and North African countries.
- Significance of International Collaboration: CEO Dwight Egan emphasized that international partnerships are crucial for closing the diagnostics gap, showcasing the company's strategy of combining cutting-edge technology with local expertise to enhance diagnostic accessibility in the region.
- AI-Integrated Platform: The Co-Dx PCR platform integrates artificial intelligence and cloud-connected outbreak surveillance capabilities designed for real-time monitoring of infectious disease trends, expected to be a component of the CoMira partnership, reflecting the company's broader strategy of deploying automated, AI-enabled diagnostics infrastructure in key international markets.
See More
SciSparc Receives Approval to Acquire Stake in Israeli Tech Firm
- Acquisition Approval: SciSparc Ltd. (SPRC) received regulatory approval from the TSX Venture Exchange for its subsidiary NeuroThera Labs to acquire approximately 54% of CliniQuantum, valued at about $9.46 million, which is expected to enhance its competitive edge in clinical trial data analysis.
- Stock Surge: SPRC's shares soared nearly 140% to close at $10.55 on Thursday, reflecting strong market enthusiasm for its acquisition plans, which may attract further investor interest in its future growth prospects.
- Ebola Testing Progress: Co-Diagnostics Inc. (CODX) saw its stock rally over 50% for the third consecutive day amid the Ebola outbreak, indicating the effectiveness of its PCR assay strategy, which is likely to bolster the company's influence in public health.
- Clinical Trial Initiation: MiNK Therapeutics (INKT) dosed its first patient in a randomized phase 2 trial for acute lung injury, leading to an 18% stock increase, and this advancement could provide crucial data support for its future treatment options, strengthening its market position.
See More
Biotech Stocks Show Significant Pre-Market Activity
- Significant Pre-Market Gains: Wellgistics Health, Inc. (WGRX) surged 29% to $4.05 in pre-market trading, indicating strong market confidence in its future growth, which may attract more investor interest.
- Other Gainers: Co-Diagnostics, Inc. (CODX) rose 11% to $8.12, while Palladyne AI Corp. (PDYN) increased 10% to $8.21, reflecting an overall positive sentiment in the biotech sector that could drive investment momentum.
- Pre-Market Decliners: AIM ImmunoTech Inc. (AIM) fell 21% to $0.32, highlighting market concerns about its outlook, which may lead investors to reassess their strategies.
- Additional Decliners: BioRestorative Therapies, Inc. (BRTX) dropped 20% to $1.30, and Aditxt, Inc. (ADTX) decreased 18% to $0.17, indicating a lack of confidence in certain biotech companies, potentially impacting their fundraising capabilities.
See More
Co-Diagnostics Completes Clinical Performance Studies for PCR Test
- Clinical Study Completion: Co-Diagnostics has completed clinical and analytical performance studies for the Co-Dx™ PCR Flu A/B and RSV upper respiratory multiplex test across 9 clinical sites, enrolling over 1,400 patients, marking a significant milestone towards the FDA submission for 510(k) and CLIA Waiver.
- Analytical Validation Data: The studies included 27 individual analytical studies and over 10,000 PCR test cup runs, providing robust evidence to support the upcoming FDA submission targeted for Q3 2026, showcasing the company's potential in the decentralized testing market.
- Reproducibility Study: An external multicenter reproducibility study demonstrated consistent performance across different operators, sites, and instruments, meeting CLIA Waiver requirements and enhancing the product's competitive edge in the market.
- Strategic Vision: CEO Dwight Egan emphasized that the platform aims to deliver accurate near-patient PCR diagnostics, and the company's ongoing efforts and forthcoming submission will lay the groundwork for future commercialization, promoting the adoption of decentralized healthcare.
See More
Co-Diagnostics Expands Mosquito Abatement Customer Base
- Customer Base Growth: Co-Diagnostics has expanded its mosquito abatement district customer base to 21 states, with four new full laboratory installations added in June, reflecting the strength of its technology and the urgent need for vector-borne disease surveillance.
- Technological Advantage: The company's Vector Smart® product line includes multiplex PCR tests for various diseases such as West Nile virus and Zika, designed to enhance situational awareness in communities and improve abatement efficiency.
- Market Demand: According to the World Health Organization, vector-borne diseases cause over 700,000 deaths annually, and Co-Diagnostics' technology enables decentralized PCR testing within communities, facilitating better coordination among public health agencies.
- Commitment to Innovation: The company is committed to remaining at the forefront of decentralized PCR technology to support global vector control and infectious disease testing, ensuring timely collection and sharing of surveillance data to protect community health.
See More
Co-Diagnostics Advances Technology Transfer with CoMira Partnership
- Technology Transfer Initiative: Co-Diagnostics' delegation from CoMira Diagnostics visited the Salt Lake City headquarters, marking a new phase in the planned technology transfer that is expected to enhance diagnostic test production capabilities in Saudi Arabia and 18 other Middle Eastern and North African countries.
- Automated Production Line Unveiling: During the visit, Co-Diagnostics unveiled its future automated PCR test kit manufacturing line, a critical facility that will support rapid scaling of diagnostic test production to meet local healthcare needs and improve operational efficiency.
- Significance of International Collaboration: CEO Dwight Egan emphasized that the partnership with CoMira reflects the belief that closing the diagnostics gap requires a blend of cutting-edge technology and local expertise, aiming to enhance diagnostic accessibility across the region.
- AI-Integrated Platform: The Co-Dx PCR platform integrates artificial intelligence and cloud-connected outbreak surveillance capabilities, which are expected to be part of the CoMira partnership, reflecting the company's strategic intent to deploy automated, AI-driven diagnostic infrastructure in key international markets.
See More
Co-Diagnostics Advances Technology Transfer with CoMira Partnership
- Technology Transfer Initiative: Co-Diagnostics is set to transfer its molecular diagnostics platform and manufacturing capabilities to CoMira Diagnostics in Saudi Arabia, which is expected to significantly enhance diagnostic test production capacity in the region to meet healthcare needs.
- Automated Production Line Unveiling: The unveiling of the future automated PCR test kit manufacturing line at the Salt Lake City headquarters will support rapid scaling of diagnostic test production, anticipated to provide efficient testing solutions for Saudi Arabia and 18 other Middle Eastern and North African countries.
- Significance of International Collaboration: CEO Dwight Egan emphasized that international partnerships are crucial for closing the diagnostics gap, showcasing the company's strategy of combining cutting-edge technology with local expertise to enhance diagnostic accessibility in the region.
- AI-Integrated Platform: The Co-Dx PCR platform integrates artificial intelligence and cloud-connected outbreak surveillance capabilities designed for real-time monitoring of infectious disease trends, expected to be a component of the CoMira partnership, reflecting the company's broader strategy of deploying automated, AI-enabled diagnostics infrastructure in key international markets.
See More
SciSparc Receives Approval to Acquire Stake in Israeli Tech Firm
- Acquisition Approval: SciSparc Ltd. (SPRC) received regulatory approval from the TSX Venture Exchange for its subsidiary NeuroThera Labs to acquire approximately 54% of CliniQuantum, valued at about $9.46 million, which is expected to enhance its competitive edge in clinical trial data analysis.
- Stock Surge: SPRC's shares soared nearly 140% to close at $10.55 on Thursday, reflecting strong market enthusiasm for its acquisition plans, which may attract further investor interest in its future growth prospects.
- Ebola Testing Progress: Co-Diagnostics Inc. (CODX) saw its stock rally over 50% for the third consecutive day amid the Ebola outbreak, indicating the effectiveness of its PCR assay strategy, which is likely to bolster the company's influence in public health.
- Clinical Trial Initiation: MiNK Therapeutics (INKT) dosed its first patient in a randomized phase 2 trial for acute lung injury, leading to an 18% stock increase, and this advancement could provide crucial data support for its future treatment options, strengthening its market position.
See More
Biotech Stocks Show Significant Pre-Market Activity
- Significant Pre-Market Gains: Wellgistics Health, Inc. (WGRX) surged 29% to $4.05 in pre-market trading, indicating strong market confidence in its future growth, which may attract more investor interest.
- Other Gainers: Co-Diagnostics, Inc. (CODX) rose 11% to $8.12, while Palladyne AI Corp. (PDYN) increased 10% to $8.21, reflecting an overall positive sentiment in the biotech sector that could drive investment momentum.
- Pre-Market Decliners: AIM ImmunoTech Inc. (AIM) fell 21% to $0.32, highlighting market concerns about its outlook, which may lead investors to reassess their strategies.
- Additional Decliners: BioRestorative Therapies, Inc. (BRTX) dropped 20% to $1.30, and Aditxt, Inc. (ADTX) decreased 18% to $0.17, indicating a lack of confidence in certain biotech companies, potentially impacting their fundraising capabilities.
See More
